<DOC>
	<DOCNO>NCT02466984</DOCNO>
	<brief_summary>Subcutaneous ( SC ) route become standard care many drug administration palliative medicine . A preliminary study show , although widely adopt among palliative care practitioner routinely prescribed medication , standard proof still lack many molecule . Among , metoclopramide largely employed drug nausea vomit treatment , particularly palliative care oncology . Therefore , investigator aim study absorption efficacy subcutaneous administration metoclopramide .</brief_summary>
	<brief_title>Subcutaneous Route Pharmacology Metoclopramide</brief_title>
	<detailed_description>In cross-over study , patient receive subcutaneous intravenous metoclopramide , randomize order administration . During perfusion phase , metoclopramide administrate continuous flow , dos increase every two day , first 10 20 20 30 mg/d . In order guarantee plasmatic balance route change , first dose second phase extend three day . Metoclopramide plasmatic concentration measure inclusion end dose administration , total 7 dosage . Principal purpose research clarify subcutaneous bioavailability metoclopramide . For meaning , mean difference subcutaneous intravenous concentration ratio compare . Secondary purpose consist : calculating metoclopramide subcutaneous bioavailability study dose ( 10 , 20 30 mg/d ) ; describe dose-bioavailability relation subcutaneous metoclopramide ; compare dose-concentration relationship intravenous subcutaneous metoclopramide ; study local tolerance check inflammatory sign surround injection site ; evaluate clinical efficacy compare two group number vomit episode , use Serotonin receptor antagonist nausea score 11-level numerical scale . Eighteen patient analyse least . For patient complete study , one include order reach eighteen necessary patient . Therefore , expect include twenty-four patient . Included population characteristic describe . A three-dimensional analysis period , subject dose perform determine metoclopramide absolute bioavailability . For secondary criterion , dose-concentration relation analyse four-dimensional analysis ; dose-bioavailability dose-concentration relation describe linear log-linear regression . For principal purpose , result patient complete study part aforementioned analyse .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Man woman &gt; 18 year Patients hospitalize palliative medical care unit University Hospital Bordeaux Patient whose life expectancy great 4 week Patients suffer nausea day inclusion great equal score 3/10 numerical scale ( FR ) 0 10 / least one vomit within three day prior inclusion Patients may infuse IV subcutaneous ( SC ) Patient communicate verbally write Patients affiliate beneficiary social security fund Patient give write consent Exclusion criterion Pregnant breastfeed woman Current Treatment severe progressive threaten disease Treatment oral injectable metoclopramide within 3 day prior inclusion Treatment levodopa dopamine agonist progress Neuroleptic Processing Patient lesion occlusive syndrome Patients risk gastrointestinal perforation Patient clinical sign gastrointestinal bleed Parkinson 's disease Patients epilepsy control antiseizure treatment Patients suffer liver failure Patients heart rate le 60 beat / min baseline Patients systolic blood pressure less equal 90 mmHg baseline History allergy metoclopramide History allergy ondansetron Previous history tardive dyskinesia neuroleptic metoclopramide Previous history pheochromocytoma Previous history methemoglobinemia metoclopramide History deficit NADHcytochrome b5 reductase Patient deprive liberty judicial administrative decision Major protect law Exclusion period Patient relative another protocol . Exclusion criterion Pregnant woman ( blood βHCG dosage ≥ 5 IU / L ) Patients creatinine clearance less equal 60 mL / min baseline Patient cardiac conduction disorder ECG Patients electrolyte imbalance electrolyte</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>metoclopramide</keyword>
	<keyword>subcutaneous route</keyword>
	<keyword>palliative care</keyword>
	<keyword>pharmacology</keyword>
	<keyword>bioavailability</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
</DOC>